Search results

22 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
UNC researchers make groundbreaking discovery, use skin cells to kill cancer
A preclinical study led by a UNC Lineberger Comprehensive Cancer Center researcher found that skin cells turned cancer-killing stem cells hunt down and destroy the deadly remnants inevitably left behind when a brain tumor is surgically removed.
Located in News
blossom-next.jpg
Blossom Damania, PhD, Assistant Dean for Research, professor of microbiology and immunology at the UNC School of Medicine and a member of UNC Lineberger Comprehensive Cancer Center.
Located in landing / / Images / 2016
Keller
February 9, 2012 Laboratory photos for Office of Cancer Genomics.
Located in Slides / Images
LCCC.jpg
Lab Operations and Automation Manager Chatura Jayakody operates the liquid handler in the Center for Integrative Chemical Biology and Drug Discovery in Marsico Hall at the University of North Carolina at Chapel Hill.
Located in Images / Faculty & Staff
Nanoparticle form of bone loss prevention drug effective against cancer, preclinical study finds
A preclinical study led by a UNC Lineberger researcher found that a nanoparticle form of a drug used to prevent bone loss was effective against small-cell lung and prostate cancer cells. The results were published in the journal Biomaterials.
Located in News
Using new drug screening tool, UNC researchers identify potential treatments for Ewing sarcoma
In a first-of-its-kind-study, researchers have discovered and applied a new screening technique capable of testing thousands of potential drug compounds to see if those compounds can reverse abnormal DNA unwinding in Ewing sarcoma, a bone and soft tissue cancer that’s most common in teens and young adults.
Located in News
UNC Startup Receives Federal Grant to Kick-Start Cancer Research Commercialization
G-Zero Therapeutics funded under Qualifying Therapeutic Discovery Project
Located in News / 2011 News
Promising treatment direction revealed for pancreatic cancers driven by KRAS mutation
In the journal Cancer Cell, UNC Lineberger researchers report findings of a promising strategy to treat KRAS-mutant pancreatic cancers. Preclinical studies showed promise for using a type of investigational drug that works by inhibiting the protein ERK, the last of a series of signals of a signaling pathway that drives drive abnormal growth of cells with KRAS mutations.
Located in News
Study finds different genetic mutation patterns for HPV-positive throat cancer patients based on smoking history
Researchers at UNC Lineberger Comprehensive Cancer Center have presented preliminary findings from a study examining the genetic alterations in HPV-positive oropharyngeal squamous cell carcinoma, a cancer of the head and neck. The researchers found differences in the genetic mutations of HPV-positive oropharyngeal cancer based on whether patients were heavy versus light smokers.
Located in News
Device hits pancreatic tumors hard with toxic four-drug cocktail, sparing the body
A new implantable device delivers first-line treatment for pancreatic cancer directly to tumors, bypassing bloodstream and limiting widespread side effects. A team of researchers from the University of North Carolina including Drs. Jen Jen Yeh and Joseph DeSimone, has shown in preclinical research that the device can deliver a particularly toxic dose of drugs directly to pancreatic tumors to stunt their growth or, in some cases, shrink them. This approach would also spare the patient toxic side effects.
Located in News